Peer-influenced content. Sources you trust. No registration required. This is HCN.

Rare Disease AdvisorImproving the Diagnosis: Evidence-Based Guidelines for the Diagnosis of Dedifferentiated Liposarcoma

Evidence-Based Guidelines for Diagnosing Dedifferentiated Liposarcoma: Linking Tumor Characteristics and Genetic Markers to Improved Clinical Outcomes

Dedifferentiated liposarcoma (DDL) is a malignancy that arises from well-differentiated liposarcoma (WDL) or atypical lipomatous tumor (ALT), with a significant potential for metastasis. Accurate diagnosis, incorporating radiographic imaging, histopathological analysis, and genetic testing, is crucial for effective management and improved prognosis. This comprehensive guide outlines the evidence-based protocols for identifying DDL, highlighting clinical presentations, diagnostic techniques, and prognostic factors.

Key Points:

  • Definition and Origin: DDL transitions from well-differentiated liposarcoma (WDL) or atypical lipomatous tumor (ALT) to a nonlipogenic sarcoma.
  • Incidence: Approximately 90% of DDL cases arise de novo, with a metastatic rate of 15% to 20%.
  • Location: Commonly occurs in the retroperitoneal space, paratesticular area, extremities, thorax, mediastinum, and head and neck.
  • Demographics: Predominantly affects middle-aged and older adults, with equal gender distribution; rare in children and adolescents.
  • Clinical Presentation: Typically presents as large, painless growths; symptoms may include abdominal distension, pain, and compression-related issues.
  • Imaging: MRI is preferred for soft-tissue lesion evaluation; PET scans can differentiate between high and low FDG uptake components.
    • MRI Findings: WDL/ALT component shows high signal intensity on T1 and T2 images; dedifferentiated component larger than 3 cm with prolonged T1 and T2 times.
    • PET Findings: High FDG uptake in dedifferentiated component; minimal FDG uptake in WDL/ALT component.
  • Histopathology: DDLs are large, multinodular tumors with varied consistency; firm demarcation between WDL and DDL components is typical.
    • Microscopic Characteristics: DDL frequently surrounds and invades adjacent organs; 60% of cases show microscopic organ invasion.
  • Grading: Federation National des Centres de Lutte Contre le Cancer grading criteria classify DDL between grades 1 and 3.
  • Immunostaining: MDM2 and CDK4 expression are key markers for differentiating DDL from poorly differentiated sarcomas.
  • Prognosis: DDL has a poorer overall survival prognosis compared to WDL; factors associated with higher mortality include older age, metastasis, retroperitoneal/abdominal primary site, and higher tumor grade.
  • Genetic Testing: Amplifications of chromosome 12q13-15 regions, including MDM2 and CDK4, are characteristic; FISH and NanoString analysis are effective diagnostic tools.
    • NanoString Analysis: Shows a 93% technical success rate and 97.8% accuracy compared to FISH, with faster and cheaper turnaround times.

Liposarcomas are the second most common soft tissue sarcoma, accounting for 20 percent of cases, though only 1,700 are diagnosed in the US each year.

More on Sarcomas

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form